Abstract
185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have